Mirum Pharmaceuticals (MIRM) Total Liabilities (2018 - 2026)

Mirum Pharmaceuticals' Total Liabilities history runs 9 years deep, the most recent figure standing at $648.4 million for Q1 2026.

• In Q1 2026, Total Liabilities rose 41.89% year-over-year to $648.4 million; the TTM figure through Mar 2026 stood at $648.4 million (up 41.89% YoY), while the FY2025 annual figure was $528.1 million, up 18.65% from the prior year.
• Total Liabilities was $648.4 million for Q1 2026 at Mirum Pharmaceuticals, up from $528.1 million in the prior quarter.
• In the past five years, Total Liabilities ranged from a high of $648.4 million in Q1 2026 to a low of $169.2 million in Q1 2022.
• Historically, Total Liabilities has averaged $378.0 million across 5 years, with a median of $417.4 million in 2024.
• The sharpest annual moves came in 2024 and 2025: Total Liabilities surged 116.95% in 2024, then gained 9.01% in 2025.
• A 5-year view of Total Liabilities shows it stood at $210.9 million in 2022, then surged by 88.72% to $398.0 million in 2023, then increased by 11.85% to $445.1 million in 2024, then grew by 18.65% to $528.1 million in 2025, then grew by 22.78% to $648.4 million in 2026.
• The last three Total Liabilities figures came in at $648.4 million (Q1 2026), $528.1 million (Q4 2025), and $493.1 million (Q3 2025), per Business Quant data.